The pancreatic cancer drug Daraxonrasib made cancer undetectable in about 8% of 61 patients with advanced disease that had spread, according to findings presented by Wungki Park in Barcelona. Tumors stopped growing in 90% of patients, giving doctors a stronger result than they have seen in years.
Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, said, "this is the closest to cure" while describing the trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. He also said, "The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible."
Barcelona trial results
The trial followed patients for a year and a half on average. Just over 60% of patients had their tumors shrink or disappear, and a year after starting treatment, 76.6% were alive. The drug is a KRAS inhibitor that works by locking on to and shutting off certain mutations found in most pancreatic cancers.
Park said, "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival." That description goes beyond shrinkage alone and points to a treatment that held disease in check for longer than standard responses usually suggest.
Michelle Mitchell on NHS use
Michelle Mitchell of Cancer Research UK said, "This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers." She added, "These results raise the exciting possibility that this breakthrough could eventually pave the way for treating other cancers that carry Kras gene mutations."
Mitchell also said, "More trials are now needed before this treatment can be assessed for use on the NHS and despite this advance, pancreatic cancer survival is still very low." In people whose pancreatic cancer has spread, survival remains poor, with about 3% alive five years later, so longer studies will need to show whether the early responses last.
KRAS and longer follow-up
The result matters because the trial does not stop at shrinkage. It includes a near-remission signal on CT scans, a higher one-year survival figure, and disease control that has now been tracked over 18 months on average.
What comes next is not a new headline number but a test of durability: whether daraxonrasib can keep advanced pancreatic cancer from returning or progressing after the trial period, and whether larger studies can reproduce the same response rates before NHS assessment moves forward.







